This inventor holds 1 USPTO granted patent. Top assignee: Biovision, Ag. Active years: 2007.
Company Filing History:
Years Active: 2007
Title: Rüdiger Hess: Innovator in Dementia Detection
Introduction
Rüdiger Hess is a notable inventor based in Hannover, Germany. He has made significant contributions to the field of medical diagnostics, particularly in the detection of progressive chronic dementia diseases. His innovative work focuses on the development of specific peptides that can aid in the early diagnosis and management of conditions such as Alzheimer's disease.
Latest Patents
Rüdiger Hess holds a patent for a "Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection agents." This invention relates to defined peptides and their quantitative determination in the body fluids of patients suffering from progressive chronic dementia. The peptides are derived from a protein precursor and are processed in a specific manner, with potential post-translational modifications. An increase in the concentrations of these peptides indicates the presence of progressive chronic dementia, allowing for better diagnosis and management of the disease.
Career Highlights
Rüdiger Hess is associated with Biovision AG, where he continues to work on innovative solutions in the medical field. His research has the potential to complement or replace traditional mini-mental scores, providing a more accurate prognosis for patients suffering from progressive chronic dementia. His work is crucial in developing therapeutic agents aimed at combating dementia-related diseases.
Collaborations
Rüdiger has collaborated with notable colleagues such as Norbert Lamping and Hans-Dieter Zucht. Their combined expertise contributes to the advancement of research in dementia detection and treatment.
Conclusion
Rüdiger Hess is a pioneering inventor whose work in dementia detection is making a significant impact in the medical field. His innovative methods and collaboration with other experts are paving the way for improved diagnostic tools and therapeutic options for patients suffering from chronic dementia diseases.